However, CD28 cosignalling, which is required for interleukin-2 induction could not be replaced by high-affinity CD3ζ CAR binding or high-density antigen engagement.

Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly ...

The CD28 signal is diminished in cancer because tumor cells do not typically express CD28 ligands (i.e., CD80 and CD86), which leads to potentially compromised activity of CD3 T cell engagers or ...

Rondo Therapeutics’ proprietary platform features CD28-targeting binders with a wide range of co-stimulatory potencies designed to boost T cell-mediated tumor killing and overcome T cell ...

CD28 is considered to be the main co-stimulatory molecule, and the second signal has the ability to activate T cells, secrete cytokines, and express cytokine receptors.

The CD28 superagonist TGN1412 caused critical illnesses linked to cytokine storms in a phase 1 clinical trial in 2006. In recent years, ...

Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term ...

Their studies in mice showed that blocking superantigen-CD28 binding by administering peptides that compete for the binding site on CD28 prevents induction of the cytokine storm.

Rondo Therapeutics Publishes Preclinical Data on RNDO-564, a Novel CD28 x Nectin-4 Co-Stimulatory Bispecific Antibody for the Treatment of Bladder Cancer Provided by Business Wire Apr 8, 2025, 11: ...

Targeting CD28 has proven challenging, however, because of safety concerns. Some patients in early clinical trials suffered the severe inflammatory reaction cytokine release syndrome, prompting ...